Follistatin / Follistatin-344: Evidence, Mechanism & Legal Status

Follistatin is an endogenous TGF-β-superfamily antagonist that binds and neutralizes myostatin (GDF-8) and activin A, removing a brake on skeletal-muscle growth.6 The FS-344 isoform is the version used in muscle therapeutics because it is processed to a circulating serum form (FS-315) that largely spares the pituitary FSH axis.6 Its popularity as a muscle-building injectable is large; its proof in that form is not. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Follistatin is not an FDA-approved drug; the consumer peptide is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is follistatin and how does it work?

Follistatin is a single-chain, cysteine-rich secreted glycoprotein produced widely in the gonads, pituitary, liver and skeletal muscle. Alternative splicing yields two precursors — FS-317 to FS-315 (longer, with an acidic C-terminal tail) and FS-288 (shorter) — plus the gene-therapy construct FS-344, the FS-315 precursor that is post-translationally processed in circulation.6 The FS-288 isoform binds cell-surface heparan-sulfate proteoglycans avidly as a tissue-anchored paracrine form, whereas FS-315 and FS-344 bind heparan sulfate weakly and circulate as a soluble serum form. Critically for safety, FS-315 has roughly 10-fold lower affinity for activin than FS-288, which is why FS-344 was chosen for muscle gene therapy: it antagonizes myostatin while minimizing disruption of the pituitary activin-inhibin-FSH axis.1

The mechanism is disinhibition of muscle growth. Myostatin and activin A signal by binding activin type II receptors (ActRIIA/ActRIIB), recruiting type I receptors (ALK4/5), and phosphorylating SMAD2/3, which suppresses pro-growth transcription and the mTOR protein-synthesis program.6 Follistatin acts upstream as a ligand trap: it binds myostatin and activin in the extracellular space, preventing receptor engagement, abrogating SMAD2/3 signaling, and thereby disinhibiting hypertrophy and, in animals, hyperplasia plus satellite-cell activation.6 Its hypertrophic effect exceeds myostatin knockout alone — muscle-specific transgenic overexpression increased muscle mass 194-327 percent versus controls, more than myostatin-null mice, indicating follistatin also neutralizes other growth-restraining ligands such as activins and GDF-11.6

Pharmacokinetics is the central obstacle. Native follistatin protein has a very short circulating half-life, on the order of one to two hours for FS-315 after systemic dosing in animal models.6 Because of this, essentially all efficacy data come from approaches that create sustained expression — AAV gene transfer giving months of tissue expression, or engineered long-acting fusions such as follistatin-Fc — not from bolus protein injection.1 The brief, intermittent serum exposure from a subcutaneous peptide bolus is pharmacokinetically unlike sustained gene-therapy expression, and whether it produces meaningful myostatin suppression in humans is unproven.

What is the evidence by indication?

No human randomized controlled trial of follistatin exists in any form. Human evidence is limited to two small open-label AAV1-FS344 gene-therapy trials with matched untreated comparators; the consumer injectable peptide has no qualifying human efficacy data. The trial registry is NCT01519349 on ClinicalTrials.gov.5

The Becker muscular dystrophy trial was a single-site, dose-ascending study of six male patients given bilateral intramuscular quadriceps AAV1.CMV.FS344 (3×10¹¹ then 6×10¹¹ vg/kg/leg).1 On the 6-minute-walk test, several patients improved substantially (+58 m and +125 m in Cohort 1; +108 m and +29 m in Cohort 2), while others showed no meaningful change. Biopsy showed increased fiber diameter (P<0.0001), reduced endomysial fibrosis, decreased central nucleation and more uniform fiber size, with the greatest benefit at high dose; pre-existing fibrosis on MRI predicted poor response.1 An earlier report of the same program documented improved ambulation.4

The sporadic inclusion body myositis trial gave six patients bilateral quadriceps rAAV1.CMV.huFS344 at 6×10¹¹ vg/kg, with a matched untreated comparison group and a concurrent exercise regimen.2 Annualized 6-minute-walk distance improved +56.0 m/year in treated subjects versus a −25.8 m/year decline in untreated (P=0.01); four of six treated subjects gained 58-153 m, and histology showed decreased fibrosis and improved regeneration.3 Both are small, open-label, non-randomized studies — promising proof of principle, Grade B, not RCT-level.

In animals follistatin robustly builds muscle: a single AAV myostatin-inhibitor gene injection sustained increased muscle mass and strength for more than two years, including in aged and dystrophic mice,7 and daily subcutaneous recombinant FS-288 produced dose-dependent gains in lean mass and reductions in fat over about 13 weeks in mice.8 The clearest anti-fibrotic data are histologic secondary findings in the gene-therapy trials plus animal models such as spinal muscular atrophy, where recombinant follistatin lessened disease severity.9 None of this is human evidence for healthy-adult muscle building.

What doses appear in the literature?

Reported strictly as information, not a protocol, and the human peptide use below has no validated efficacy or safety data. The only human data are gene therapy: AAV1.CMV.FS344 delivered by direct bilateral intramuscular quadriceps injection, ultrasound-guided, 3×10¹¹ to 6×10¹¹ vg/kg per leg, with peri-procedure prednisone for immune modulation.1 This is a one-time viral-vector administration producing sustained local expression — not a repeat-injection peptide regimen. In preclinical work, daily subcutaneous recombinant follistatin (FS-288) over weeks produced dose-dependent muscle gains in mice, and long-acting engineered fusions are being explored to overcome the short native half-life.8 Anecdotally, lyophilized "Follistatin-344" is reconstituted in bacteriostatic water and self-administered subcutaneously at roughly 50-300 mcg/day in short cycles — but no clinical trial supports any of these doses, frequencies, routes or the efficacy of injectable follistatin in humans, and given the short half-life the pharmacokinetic rationale is weak. It is reported here only to document the gray market, not as an endorsement or protocol.

How safe is follistatin?

Across both AAV1-FS344 trials, investigators reported no significant adverse events related to gene transfer, no liver, kidney or marrow toxicity, and no disruption of pituitary or gonadal hormones — FSH, LH, testosterone and estrogen remained normal — with low anti-follistatin and anti-AAV1 antibody titers.1 The caveat is decisive: these are tiny cohorts (n=6) with localized intramuscular delivery and short follow-up, so they do not establish long-term or systemic-exposure safety.

The important safety story is mechanistic. By trapping activin A, follistatin removes a physiologic growth-inhibitory and pro-apoptotic brake on cells. In oncology models follistatin has tumorigenic and pro-angiogenic functions — it can shield cancer cells from activin-A-induced apoptosis, and the FS-288 isoform can promote tumor microvascularization.1113 Elevated serum follistatin correlates with higher tumor stage, microvessel density and worse recurrence-free survival in thymic epithelial tumors.12 The role is genuinely dichotomous, but the net signal is enough to flag caution in anyone with cancer or elevated cancer risk.11 Additional concerns include connective-tissue lag injury when rapid hypertrophy outpaces tendon adaptation; theoretical cardiovascular effects from sustained pathway antagonism (the related ACE-031 program was halted partly over vascular/bleeding signals); disease-context harm, since forcing hypertrophy can accelerate degeneration in fragile-fiber diseases such as dysferlinopathy;10 and the unverified identity, purity, sterility and endotoxin status of gray-market research-chemical vials. Theoretical caution populations include active or prior malignancy, pregnancy and lactation, and any athlete subject to anti-doping testing.

What is the FDA and WADA status in 2026?

No follistatin product is FDA-approved for any indication as of 2026. The AAV1-FS344 work was conducted under investigational clinical trials, not an approved therapy; there is no approved follistatin drug and no established compounding bulk substance for 503A/503B pharmacy use. The "Follistatin-344" peptide sold online is an unapproved new drug or research chemical typically labeled "for research use only — not for human consumption," so marketing it for human muscle-building or therapeutic use is outside any FDA authorization. It is not a DEA-controlled substance. Compounding bulk-substance and enforcement lists are periodically updated, so current FDA postings should be verified directly.

For athletes the picture is unambiguous. Follistatin is prohibited at all times, in and out of competition, under WADA Section S4.3, "Agents Preventing Activin Receptor IIB Activation," which explicitly names myostatin-binding proteins such as follistatin alongside decoy activin receptors, anti-ActRIIB antibodies and anti-myostatin antibodies.14 Increasing follistatin activity by gene transfer is additionally prohibited under the M3 gene- and cell-doping rules. Athletes should treat follistatin in any form, including so-called sport-certified follistatin supplements, as banned at all times.15

Bottom line. Follistatin is a genuine therapeutic target with real early signal in serious muscle disease — graded B for localized gene therapy, not RCT-level — and an over-hyped, unvalidated and potentially risky shortcut when sold as a muscle-building injectable, where the evidence is Grade D. Key uncertainties are long-term and systemic safety, especially cancer, whether intermittent peptide dosing does anything meaningful in humans, and durability beyond a few months. It is not FDA-approved, sold only as a research chemical, and banned in sport at all times. Regulatory facts here are current as of June 2026 and should be re-verified, as compounding and prohibited-list postings are periodically updated.